Fundamentals - Snapshot

Snapshot | Trading Statistics | Balance Sheet | Income Statement | Cash Flow | Ratios
All financial information has been updated to reflect the results of the global pharmaceuticals business as discontinued operations, consistent with the current presentation in our Form 8-K filed with the U.S. S.E.C on January 29, 2010.
Revenue & Earnings
Revenue (FY)76,694.00
EBIT (Mil) (FY)15,374.00
EBITDA (Mil) (FY)18,456.00
Net Income Excluding Extraordinary Items (Mil) (FY)10,680.00
Net Income Including Extraordinary Items (Mil) (FY)13,436.00
Diluted EPS Excluding Extraordinary Items (FY)3.39
Diluted EPS Including Extraordinary Items (FY)4.26
Dividends
Yield (%)3.15
Dividend Record Date07/23/2010
Dividend Rate1.93
Ratios
Price to Revenue (TTM)2.26
Price To Cash Flow (TTM)12.52
Price to Book (MRQ)2.70
Total Debt to Equity (MRQ) (%)45.12
Current Ratio (MRQ).92
Growth
5-Year Annual Dividend Growth Rate (%)12.01
5-Year Annual Revenue Growth Rate (%)8.33
FY = Fiscal Year MRQ = Most Recent Quarter
mil = Millions TTM = Trailing Twelve Months
Powered by Thomson Reuters